Injecting Hope - GLP-1 Receptor Agonists for the Treatment of Alcohol Use Disorder
-
Register
- Administrative Staff - Free!
- Counselor (CAADE, CADTP, CCAPP, LPC, LMHC NCC, etc.) - Free!
- PhD - Free!
- Nurse (MSN, LPN, RN, LVN) - Free!
- Nurse Practitioner (APRN, DNP) - Free!
- Pharmacist (PharmD) - Free!
- Physician (MD) - Free!
- Physician (DO) - Free!
- Physician (MBBS) - Free!
- Physician Associate (PA-C) - Free!
- Psychologist (PsyD) - Free!
- Social Worker (MSW, LCSW, LGSW) - Free!
- Student/Resident/Fellow - Free!
- Other - Free!
Injecting Hope - GLP-1 Receptor Agonists for the Treatment of Alcohol Use Disorder
Host: American Academy of Addiction Psychiatry
Recorded: July 29, 2026
Enduring Training
Overview
This training explores the pharmacology of GLP-1 medications and examine the growing body of research investigating their impact on alcohol cravings and recovery outcomes. Participants will review emerging evidence supporting the use of GLP-1s for alcohol use disorder, while also considering important clinical questions, limitations, and concerns surrounding their use in this evolving area of addiction treatment.
The target audience for this introductory level activity includes: All types of healthcare professionals.
The ACGME Competencies include: Medical Knowledge, Patient Care and Procedural Skills, and Systems-based Practice
Learning Objectives
Upon completion, learners will be able to:
- Describe the pharmacology of GLP-1 receptor agonists
- Evaluate the emerging evidence base to support their use in treatingsubstance use disorders
- Outline concerns being raised surrounding the use of GLP1s for SUD
- Registration Deadline: 08/30/2027
- Close Access Date: 09/30/2027
Instructions
- Click on the Contents tab to begin this activity.
- Click View On-Demand Session to watch the training.
- Click Complete GPRA Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click Claim Certificate of Completion to view/print certificate.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page, or contact pcssmaud@asam.org.
Joji Suzuki, MD
Dr Suzuki is the Director of the Division of Addiction Psychiatry in the Department of Psychiatry, Brigham and Women’s Hospital (BWH), and an Assistant Professor of Psychiatry at Harvard Medical School (HMS). He has been a consultation-liaison psychiatrist in the Division of Medical Psychiatry at BWH, and serves as the Program Director for the BWH Addiction Medicine Fellowship Program. He has been very active in both medical student and resident education throughout his career. He is a member of Motivational Interviewing Network of Trainers and is the course director for the HMS CME course on motivational interviewing. His research has received funding from National Institute on Drug Abuse (NIDA), CDC, SAMHSA, BWH, and HMS. In 2018 he was awarded a NIDA K23 Career Development Award to receive mentored training in conducting clinical trials, and to study the impact of recovery coaches on hospitalized patients with opioid use disorder. He is a sought-out speaker both locally and nationally, and currently serves on a variety of committees, workgroups, and taskforces for Mass General Brigham, HMS, American Academy of Addiction Psychiatry, Academy of Consultation Liaison Psychiatry, and the State of Massachusetts. He has published 80 manuscripts and book chapters as first or co-author.
Disclosure Information
In accordance with the disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all accredited continuing education activities. These policies include identifying and mitigating all relevant financial relationships with ineligible companies for those involved in the creation and dissemination of accredited continuing education.
This activity is not for credit.
Key:
Complete
Next
Failed
Available
Locked